Dominant effects of Δ40p53 on p53 function and melanoma cell fate

Journal of Investigative Dermatology

Volumn 134, Issue 3, 2014, Pages 791-800

  Takahashi, Rie ^a,b   Markovic, Svetomir N ^a   Scrable, Heidi J ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1A; DELTA 40P53 PROTEIN; LENTIVIRUS VECTOR; PROTEIN MDM2; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; CYCLIN B1; CYCLOHEXIMIDE; DELTA40P53; GREEN FLUORESCENT PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; P53 INDUCED PROTEIN WITH DEATH DOMAIN; PROPIDIUM IODIDE; PROTEIN; PROTEIN P21; SERINE; TETRAMER;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL DEATH; CELL FATE; CONTROLLED STUDY; EMBRYO; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; TRANSACTIVATION; CELL GROWTH; CELL LYSATE; CELL NUCLEUS; CELL VIABILITY; CELLULAR DISTRIBUTION; CHROMATIN IMMUNOPRECIPITATION; CYTOPLASM; ENDOPLASMIC RETICULUM STRESS; FIBROBLAST; FLOW CYTOMETRY; GAMMA IRRADIATION; GENE MUTATION; GENE OVEREXPRESSION; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; LENTIVIRINAE; MELANOCYTE; MELANOMA CELL LINE; PROMOTER REGION; SPLEEN FOCUS FORMING VIRUS; UNFOLDED PROTEIN RESPONSE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BRAIN NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEINS; FIBROBLASTS; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MELANOCYTES; MELANOMA; MICE; PROMOTER REGIONS, GENETIC; PROTEIN STRUCTURE, TERTIARY; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84894099506     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2013.391     Document Type: Article

References (66)

1. Albino AP, Vidal MJ, McNutt NS et al. (1994) Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res 4: 35-455
2. Anensen N, Oyan AM, Bourdon JC et al. (2006) A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia. Clin Cancer Res 12:3985-922
3. Avery-Kiejda KA, Bowden NA, Croft AJ et al. (2011) P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation. BMC Cancer 11:2033
4. Avery-Kiejda KA, Zhang XD, Adams LJ et al. (2008) Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. Clin Cancer Res 14: 1659-688
5. Banin S, Moyal L, Shieh S et al. (1998) Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281:1674-77
6. Beckerman R, Prives C (2010) Transcriptional regulation by p53. Cold Spring Harbor Perspect Biol 2:a0009355
7. Belyi VA, Ak P, Markert E et al. (2010) The origins and evolution of the p53 family of genes. Cold Spring Harb Perspect Biol 2:a0011988
8. Bhattacharya S, Ray RM, Johnson LR (2009) Role of polyamines in p53-dependent apoptosis of intestinal epithelial cells. Cell Signal 21: 509-222
9. Boldrup L, Bourdon JC, Coates PJ et al. (2007) Expression of p53 isoforms in squamous cell carcinoma of the head and neck. Eur J Cancer 43:617-233
10. Bourdon JC, Fernandes K, Murray-Zmijewski F et al. (2005a) P53 isoforms can regulate p53 transcriptional activity. Genes Dev 19:2122-377
11. Bourdon JC, Fernandes K, Murray-Zmijewski F et al. (2005b) P53 isoforms can regulate p53 transcriptional activity. Genes Dev 19:2122-377
12. Budihardjo II, Poirier GG, Kaufmann SH (1998) Apparent cleavage of poly(ADP-ribose) polymerase in non-apoptotic mouse LTA cells: an artifact of cross-reactive secondary antibody. Mol Cell Biochem 178: 245-99
13. Canman CE, Lim DS, Cimprich KA et al. (1998) Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281:1677-99
14. Carlson BL, Pokorny JL, Schroeder MA et al. (2011) Establishment, maintenance and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM) xenograft models for translational biology studies and drug discovery. Curr Protoc Pharmacol Chapter 14(Unit 14):66
15. Cheok CF, Verma CS, Baselga J et al. (2011) Translating p53 into the clinic. Nat Rev Clin Oncol 8:25-377
16. Courtois S, Verhaegh G, North S et al. (2002) DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene 21:6722-88
17. Crescenzi E, Palumbo G, de Boer J et al. (2008) Ataxia telangiectasia mutated and p21CIP1 modulate cell survival of drug-induced senescent tumor cells: implications for chemotherapy. Clin Cancer Res 14:1877-877
18. Danovi D, Meulmeester E, Pasini D et al. (2004) Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol Cell Biol 24:5835-433
19. Demaison C, Parsley K, Brouns G et al. (2002) High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 13:803-133
20. Gembarska A, Luciani F, Fedele C et al. (2012) MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med 18:1239-477
21. Ghosh A, Stewart D, Matlashewski G (2004) Regulation of human p53 activity and cell localization by alternative splicing. Mol Cell Biol 24:7987-977
22. Goldstein I, Marcel V, Olivier M et al. (2011) Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. Cancer Gene Ther 18:2-111
23. Grover R, Candeias MM, Fahraeus R et al. (2009) P53 and little brother p53/47: linking IRES activities with protein functions. Oncogene 28:2766-722
24. Grover R, Ray PS, Das S (2008) Polypyrimidine tract binding protein regulates IRES-mediated translation of p53 isoforms. Cell Cycle 7:2189-988
25. Grover R, Sharathchandra A, Ponnuswamy A et al. (2011) Effect of mutations on the p53 IRES RNA structure: implications for de-regulation of the synthesis of p53 isoforms. RNA Biol 8:132-422
26. Gwosdz C, Scheckenbach K, Lieven O et al. (2006) Comprehensive analysis of the p53 status in mucosal and cutaneous melanomas. Int J Cancer 118:577-822
27. Hollstein M, Hainaut P (2010) Massively regulated genes: the example of TP53. J Pathol 220:164-733
28. Hollstein M, Sidransky D, Vogelstein B et al. (1991) P53 mutations in human cancers. Science 253:49-533
29. Houben R, Hesbacher S, Schmid CP et al. (2011) High-level expression of wild-type p53 in melanoma cells is frequently associated with inactivity in p53 reporter gene assays. PLoS One 6:e220966
30. Ito K, Kiyosawa N, Kumagai K et al. (2006) Molecular mechanism investigation of cycloheximide-induced hepatocyte apoptosis in rat livers by morphological and microarray analysis. Toxicology 219:175-866
31. Ji Z, Njauw CN, Taylor M et al. (2012) P53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition. J Invest Dermatol 132:356-644
32. Kaufmann WK, Nevis KR, Qu P et al. (2008) Defective cell cycle checkpoint functions in melanoma are associated with altered patterns of gene expression. J Invest Dermatol 128:175-877
33. Khanna KK, Keating KE, Kozlov S et al. (1998) ATM associates with and phosphorylates p53: mapping the region of interaction. Nat Genet 20:398-4000
34. Khoury MP, Bourdon JC (2010) The isoforms of the p53 protein. Cold Spring Harb Perspect Biol 2:a0009277
35. Kichina JV, Rauth S, Das Gupta TK et al. (2003) Melanoma cells can tolerate high levels of transcriptionally active endogenous p53 but are sensitive to retrovirus-transduced p53. Oncogene 22:4911-77
36. Knopf A, Plettenberg C, Pickhard A et al. (2011) Analysis of the functional integrity of the p53 tumor-suppressor gene in malignant melanoma. Melanoma Res 21:380-88
37. Lane D, Levine A (2010) P53 research: the past thirty years and the next thirty years. Cold Spring Harb Perspect Biol 2:a0008933
38. Lane DP, Cheok CF, Lain S (2010) P53-based cancer therapy. Cold Spring Harbor Perspect Biol 2:a0012222
39. Levine AJ, Momand J, Finlay CA (1991) The p53 tumour suppressor gene. Nature 351:453-66
40. Li W, Sanki A, Karim RZ et al. (2006) The role of cell cycle regulatory proteins in the pathogenesis of melanoma. Pathology 38:287-3011
41. Machado-Silva A, Perrier S, Bourdon JC (2010) P53 family members in cancer diagnosis and treatment. Semin Cancer Biol 20:57-622
42. Maier B, Gluba W, Bernier B et al. (2004a) Modulation of mammalian life span by the short isoform of p53. Genes Dev 18:306-199
43. Maier B, Gluba W, Bernier B et al. (2004b) Modulation of mammalian life span by the short isoform of p53. Genes Dev 18:306-199
44. Marcel V, Dichtel-Danjoy ML, Sagne C et al. (2011) Biological functions of p53 isoforms through evolution: lessons from animal and cellular models. Cell Death Differ 18:1815-244
45. Marcel V, Perrier S, Aoubala M et al. (2010) Delta160p53 is a novel N-terminal p53 isoform encoded by Delta133p53 transcript. FEBS Lett 584:4463-88
46. Medrano S, Burns-Cusato M, Atienza MB et al. (2009a) Regenerative capacity of neural precursors in the adult mammalian brain is under the control of p53. Neurobiol Aging 30:483-977
47. Medrano S, Burns-Cusato M, Atienza MB et al. (2009b) Regenerative capacity of neural precursors in the adult mammalian brain is under the control of p53. Neurobiol Aging 30:483-977
48. Mills AA (2005) P53: link to the past, bridge to the future. Genes Dev 19:2091-99
49. Montano X, Shamsher M, Whitehead P et al. (1994) Analysis of p53 in human cutaneous melanoma cell lines. Oncogene 9:1455-99
50. Muthusamy V, Hobbs C, Nogueira C et al. (2006) Amplification of CDK4 and MDM2 in malignant melanoma. Genes Chromosomes Cancer 45:447-544
51. Oliver FJ, de la Rubia G, Rolli V et al. (1998) Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant. J Biol Chem 273:33533-99
52. Oren M, Rotter V (2010) Mutant p53 gain-of-function in cancer. Cold Spring Harbor Perspect Biol 2:a0011077
53. Petitjean A, Mathe E, Kato S et al. (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28:622-99
54. Powell DJ, Hrstka R, Candeias M et al. (2008) Stress-dependent changes in the properties of p53 complexes by the alternative translation product p53/47. Cell Cycle 7:950-99
55. Robles AI, Harris CC (2010) Clinical outcomes and correlates of TP533 mutations and cancer. Cold Spring Harb Perspect Biol 2:a0010166
56. Shenkman M, Tolchinsky S, Lederkremer GZ (2007) ER stress induces alternative nonproteasomal degradation of ER proteins but not of cytosolic ones. Cell Stress Chaperones 12:373-833
57. Siliciano JD, Canman CE, Taya Y et al. (1997) DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev 11:3471-811
58. Soto JL, Cabrera CM, Serrano S et al. (2005) Mutation analysis of genes that control the G1/S cell cycle in melanoma: TP53, CDKN1A, CDKN2A, and CDKN2B. BMC Cancer 5:366
59. Takahashi R, Giannini C, Sarkaria JN et al. (2012) P53 isoform profiling in glioblastoma and injured brain. Oncogene 32:3165-744
60. Terzian T, Torchia EC, Dai D et al. (2010) P53 prevents progression of nevi to melanoma predominantly through cell cycle regulation. Pigment Cell Melanoma Res 23:781-944
61. Ungewitter E, Scrable H (2010a) Delta40p53 controls the switch from pluripotency to differentiation by regulating IGF signaling in ESCs. Genes Dev 24:2408-199
62. Ungewitter E, Scrable H (2010b) Delta40p53 controls the switch from pluripotency to differentiation by regulating IGF signaling in ESCs. Genes Dev 24:2408-199
63. Vousden KH, Prives C (2009) Blinded by the Light: The Growing Complexity of p53. Cell 137:413-311
64. Weiss J, Heine M, Arden KC et al. (1995) Mutation and expression of TP53 in malignant melanomas. Recent Results Cancer Res 139:137-544
65. Yin Y, Stephen CW, Luciani MG et al. (2002) P53 stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products. Nat Cell Biol 4:462-77
66. Zerp SF, van Elsas A, Peltenburg LT et al. (1999) P53 mutations in human cutaneous melanoma correlate with sun exposure but are not always involved in melanomagenesis. Br J Cancer 79:921-66